A study showed that bladder cancer cells treated with a CD44 inhibitor had a tendency to reduce the sizes and numbers of tumorospheres [43], indicating that USP28 can play a vital role in tumor progression by mediating CD44. This evidence concerns the gene CD44 and urinary bladder carcinoma.